Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pathogenesis and treatment of immune-mediated neuropathies.

Literature DB >> 21179533

Pathogenesis and treatment of immune-mediated neuropathies.

Helmar C Lehmann¹, Gerd Meyer Zu Horste, Bernd C Kieseier, Hans-Peter Hartung.

Abstract

Immune-mediated neuropathies represent a heterogeneous spectrum of peripheral nerve disorders that can be classified according to time course, predominant involvement of motor/sensory fibers, distribution of deficits and paraclinical parameters such as electrophysiology and serum antibodies. In the last few years, significant advances have been achieved in elucidating underlying pathomechanisms, which made it possible to identify potential therapeutic targets. In this review, we discuss the latest development in pathogenesis and treatment of immune-mediated neuropathies.

Entities: Disease

Keywords: Guíllan-Barré syndrome; cidp; immune neuropathies; paraproteinemic neuropathies; treatments

Year: 2009 PMID： 21179533 PMCID： PMC3002632 DOI： 10.1177/1756285609104792

Source DB: PubMed Journal: Ther Adv Neurol Disord ISSN： 1756-2856 Impact factor: 6.570

192 in total

1. Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population.

Authors: M Iijima; H Koike; N Hattori; A Tamakoshi; M Katsuno; F Tanaka; M Yamamoto; K Arimura; G Sobue
Journal: J Neurol Neurosurg Psychiatry Date: 2008-01-25 Impact factor: 10.154

Review 2. The immunobiology of Guillain-Barré syndromes.

Authors: Hugh J Willison
Journal: J Peripher Nerv Syst Date: 2005-06 Impact factor: 3.494

3. Power spectrum analysis of heart rate variability in Guillain-Barré syndrome. A longitudinal study.

Authors: P Flachenecker; H P Hartung; K Reiners
Journal: Brain Date: 1997-10 Impact factor: 13.501

4. Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H).

Authors: C Hirst; S Raasch; G Llewelyn; N Robertson
Journal: J Neurol Neurosurg Psychiatry Date: 2006-06 Impact factor: 10.154

5. Anti-MAG IgM penetration into myelinated fibers correlates with the extent of myelin widening.

Authors: M F Ritz; B Erne; F Ferracin; A Vital; C Vital; A J Steck
Journal: Muscle Nerve Date: 1999-08 Impact factor: 3.217

6. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy.

Authors: M C Dalakas; R H Quarles; R G Farrer; J Dambrosia; S Soueidan; D P Stein; E Cupler; E A Sekul; C Otero
Journal: Ann Neurol Date: 1996-11 Impact factor: 10.422

Review 7. Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy.

Authors: Kenneth C Gorson; Anthony A Amato; Allan H Ropper
Journal: Neurology Date: 2004-08-24 Impact factor: 9.910

8. Accumulation of Valpha7.2-Jalpha33 invariant T cells in human autoimmune inflammatory lesions in the nervous system.

Authors: Zsolt Illés; Michio Shimamura; Jia Newcombe; Nobuyuki Oka; Takashi Yamamura
Journal: Int Immunol Date: 2004-02 Impact factor: 4.823

9. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines.

Authors: T Lasky; G J Terracciano; L Magder; C L Koski; M Ballesteros; D Nash; S Clark; P Haber; P D Stolley; L B Schonberger; R T Chen
Journal: N Engl J Med Date: 1998-12-17 Impact factor: 91.245

10. Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial.

Authors: Sanne Piepers; Renske Van den Berg-Vos; W-Ludo Van der Pol; Hessel Franssen; John Wokke; Leonard Van den Berg
Journal: Brain Date: 2007-07-10 Impact factor: 13.501

13 in total

1. Neurofascin as a target for autoantibodies in peripheral neuropathies.

Authors: Judy King Man Ng; Joachim Malotka; Naoto Kawakami; Tobias Derfuss; Mohsen Khademi; Tomas Olsson; Christopher Linington; Masaaki Odaka; Björn Tackenberg; Harald Prüss; Jan M Schwab; Lutz Harms; Hendrik Harms; Claudia Sommer; Matthew N Rasband; Yael Eshed-Eisenbach; Elior Peles; Reinhard Hohlfeld; Nobuhiro Yuki; Klaus Dornmair; Edgar Meinl
Journal: Neurology Date: 2012-10-24 Impact factor: 9.910

Pathogenesis and treatment of immune-mediated neuropathies.

1. Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population.

Review 2. The immunobiology of Guillain-Barré syndromes.

3. Power spectrum analysis of heart rate variability in Guillain-Barré syndrome. A longitudinal study.

4. Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H).

5. Anti-MAG IgM penetration into myelinated fibers correlates with the extent of myelin widening.

6. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy.

Review 7. Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy.

8. Accumulation of Valpha7.2-Jalpha33 invariant T cells in human autoimmune inflammatory lesions in the nervous system.

9. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines.

10. Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial.

1. Neurofascin as a target for autoantibodies in peripheral neuropathies.

Review 2. [Differential diagnostics of diseases of the brachial plexus].

Review 3. Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond.

4. Nerve Imaging, Electrodiagnostics, and Clinical Examination - Three Musketeers to Differentiate Polyneuropathies.

5. Treatment-related Fluctuations in Guillain Barre Syndrome and the Conundrum of Additional Cycles of Plasmapheresis.

6. Immune-Mediated Autonomic Neuropathies following Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia.

7. Acute flaccid myelitis associated with enterovirus D68 in a non-epidemic setting.

8. Loss of Schwann cell plasticity in chronic inflammatory demyelinating polyneuropathy (CIDP).

9. Immune-mediated Neuropathies Our Experience over 3 Years.

Review 10. Associated conditions in small fiber neuropathy - a large cohort study and review of the literature.